These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 26484408)
21. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Lamos EM; Hedrington M; Davis SN Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300 [TBL] [Abstract][Full Text] [Related]
22. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report. Lane S; Paskar D; Hamed S; Goffi A A A Pract; 2018 Jul; 11(2):46-48. PubMed ID: 29634546 [TBL] [Abstract][Full Text] [Related]
23. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170 [TBL] [Abstract][Full Text] [Related]
24. Canagliflozin/metformin Fixed-dose Combination: National Evidence, Global Relevance. Kalra S; Kapoor N J Assoc Physicians India; 2024 Apr; 72(4):11. PubMed ID: 38881076 [No Abstract] [Full Text] [Related]
25. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents. Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon. Ren DY; Zhang Y Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274 [TBL] [Abstract][Full Text] [Related]
27. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Davidson JA; Sloan L Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055 [TBL] [Abstract][Full Text] [Related]
28. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning. Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074 [No Abstract] [Full Text] [Related]
29. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774 [TBL] [Abstract][Full Text] [Related]
30. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. Kumar S; Khatik GL; Mittal A Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370 [TBL] [Abstract][Full Text] [Related]
31. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497 [TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices? Patoulias D; Papadopoulos C; Doumas M Int J Cardiol; 2021 Jan; 323():259. PubMed ID: 32810546 [No Abstract] [Full Text] [Related]
33. [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus]. Gorgojo-Martínez JJ Hipertens Riesgo Vasc; 2019; 36(3):145-161. PubMed ID: 31079957 [TBL] [Abstract][Full Text] [Related]
34. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337 [TBL] [Abstract][Full Text] [Related]
35. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. de Wit HM; Te Groen M; Rovers MM; Tack CJ Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973 [TBL] [Abstract][Full Text] [Related]
37. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Rahman W; Solinsky PJ; Munir KM; Lamos EM Expert Opin Pharmacother; 2019 Feb; 20(2):151-161. PubMed ID: 30412008 [TBL] [Abstract][Full Text] [Related]
38. SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists. Davidson MB Ann Intern Med; 2019 Dec; 171(12):JC70. PubMed ID: 31842228 [No Abstract] [Full Text] [Related]
39. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk. Bailey CJ Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565 [No Abstract] [Full Text] [Related]
40. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]